Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Published Phase 2 effect sizes most prominently the ~24 percent mean body weight reduction at the 12 mg dose tier in the obesity Phase 2 (PMID 37366315) exceed those reported for dual or single agonists at comparable durations, an outcome that researchers attribute to the additional glucagon-arm contribution to body-composition and energy-expenditure pathways
Bottom line: Pick a GLP-1 based on your main goal (weight loss vs blood-sugar control), dosing preference, cardiovascular profile, and what your insuranceor an Rx.com discountwill actually cover
This testing identifies your predisposition across 49 peptides and 150+ metabolic insights, helping optimize your long-term therapy
FAQs: Got Questions
US$ 28.47
US$ 25.22
US$ 24.43
US$ 20.90
US$ 29.16
US$ 23.24
US$ 27.83
